The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: A Turkish oncology group kidney cancer consortium (TKCC) study

Basit Öğe Kaydı
dc.authoridSaadettin Kılıçkap / 0000-0003-1637-7390en_US
dc.authorwosidSaadettin Kılıçkap / AAP-3732-2021en_US
dc.contributor.authorTural, Deniz
dc.contributor.authorYekedüz, Emre
dc.contributor.authorErtürk, İsmail
dc.contributor.authorKarakaya, Serdar
dc.contributor.authorErol, Cihan
dc.contributor.authorErcelep, Özlem
dc.contributor.authorArslan, Çağatay
dc.contributor.authorSever, Özlem Nuray
dc.contributor.authorŞentürk Öztaş, Nihan
dc.contributor.authorKüçükarda, Ahmet
dc.contributor.authorCan, Orçun
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorŞendur, Mehmet Ali
dc.contributor.authorKaradurmuş, Nuri
dc.contributor.authorUrun, Yüksel
dc.contributor.authorKılıçkap, Saadettin
dc.date.accessioned2022-06-03T07:38:01Z
dc.date.available2022-06-03T07:38:01Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümüen_US
dc.description.abstractBackground Pan-immune-infammation value (PIV) is an easily accessible immune marker based on peripheral blood to estimate prognosis in patients with cancer. This study evaluates the prognostic value of PIV in patients with metastatic renal cell carcinoma (mRCC) treated with nivolumab. Methods In this retrospective cohort study, patients with mRCC treated with nivolumab in the second line and beyond were selected from the Turkish Oncology Group Kidney Cancer Consortium (TKCC) database. PIV was calculated using the following formula: neutrophil (103 /mm3 ) x monocyte (103 /mm3 ) x platelet (103 /mm3 )/lymphocyte (103 /mm3 ). Results A total of 152 patients with mRCC were included in this study. According to cut-of value for PIV, 77 (50.7%) and 75 (49.3%) patients fell into PIV-low (? 372) and PIV-high (>372) groups, respectively. In multivariate analysis, PIV-high (HR: 1.64, 95% CI 1.04–2.58, p=0.033 for overall survival (OS); HR: 1.55, 95% CI 1.02–2.38, p=0.042 for progression-free survival (PFS)) was independent risk factor for OS and PFS after adjusting for confounding variables, such as performance score, the International mRCC Database Consortium (IMDC) risk score, and liver metastasis. Conclusion This study established that pre-treatment PIV might be a prognostic biomarker in patients with mRCC treated with nivolumab in the second line and beyond.en_US
dc.identifier.citationYekedüz E, Tural D, Ertürk İ, Karakaya S, Erol C, Ercelep Ö, Arslan Ç, Sever ÖN, Kılıçkap S, Şentürk Öztaş N, Küçükarda A, Can O, Öksüzoğlu B, Şendur MA, Karadurmuş N, Ürün Y. The relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: a Turkish oncology group kidney cancer consortium (TKCC) study. J Cancer Res Clin Oncol. 2022 May 26. doi: 10.1007/s00432-022-04055-5. Epub ahead of print. PMID: 35616728.en_US
dc.identifier.doi10.1007/s00432-022-04055-5en_US
dc.identifier.issn0171-5216en_US
dc.identifier.pmid35616728en_US
dc.identifier.scopus2-s2.0-85130706906en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttp://doi.org/10.1007/s00432-022-04055-5
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2791
dc.identifier.wosWOS:000800433700002en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKılıçkap, Saadettin
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofJournal of Cancer Research and Clinical Oncologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectImmunotherapyen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectBiomarkeren_US
dc.titleThe relationship between pan-immune-inflammation value and survival outcomes in patients with metastatic renal cell carcinoma treated with nivolumab in the second line and beyond: A Turkish oncology group kidney cancer consortium (TKCC) studyen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
Yekedüz2022_Article_TheRelationshipBetweenPan-immu.pdf
Boyut:
889.2 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu